Riglet, François http://orcid.org/0000-0003-2696-8661
Bertrand, Julie
Barrail-Tran, Aurélie
Verstuyft, Céline
Michelon, Hugues
Benech, Henri
Durrbach, Antoine
Furlan, Valérie
Barau, Caroline
Funding for this research was provided by:
Assistance Publique - Hôpitaux de Paris
Article History
First Online: 6 October 2020
Declarations
:
: This work was supported by a grant from the Hospital Clinical Research Program of the French Ministry of Health. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
: François Riglet, Julie Bertrand, Aurélie Barrail-Tran, Céline Verstuyft, Hugues Michelon, Henri Benech, Antoine Durrbach, Valérie Furlan and Caroline Barau have no conflicts of interest that are directly relevant to the content of this article.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Patients signed informed consent regarding publishing their data.
: The data supporting the findings of this study are available on request to the corresponding author. The data are not publicly available because of privacy or ethical restrictions.
: Monolix codes are available upon request to the corresponding author.
: AD and VF designed the research. CB, ABT and VF performed the assays of plasma MPA concentrations and participated in the clinical and pharmacokinetic interpretation of the study. HB performed the assay of the cellular MPA concentrations. CV carried out the genotyping. FR analysed the data and performed the pharmacokinetic modelling under the supervision of JB. All authors participated in writing the manuscript.